Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety

Burcu Zeydan

doi:10.1016/j.ejpn.2023.03.003

Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety

Radiology

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	A1
Journal	European Journal of Paediatric Neurology
Volume	43
DOIs	https://doi.org/10.1016/j.ejpn.2023.03.003
State	Published - Mar 2023

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Clinical Neurology

Access to Document

10.1016/j.ejpn.2023.03.003

Cite this

@article{d140bc5a3fbc411999eb638ebea09e15,

title = "Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety",

author = "Burcu Zeydan",

note = "Funding Information: B. Zeydan reports funding from the NIH (NIA: U54 AG44170 ) and is supported by the Mayo Clinic Eugene and Marcia Applebaum Award.",

year = "2023",

month = mar,

doi = "10.1016/j.ejpn.2023.03.003",

language = "English (US)",

volume = "43",

pages = "A1",

journal = "European Journal of Paediatric Neurology",

issn = "1090-3798",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Ocrelizumab in pediatric patients with MS

T2 - Efficacy, tolerability, and safety

AU - Zeydan, Burcu

N1 - Funding Information: B. Zeydan reports funding from the NIH (NIA: U54 AG44170 ) and is supported by the Mayo Clinic Eugene and Marcia Applebaum Award.

PY - 2023/3

Y1 - 2023/3

UR - http://www.scopus.com/inward/record.url?scp=85151477729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151477729&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2023.03.003

DO - 10.1016/j.ejpn.2023.03.003

M3 - Editorial

C2 - 36990951

AN - SCOPUS:85151477729

SN - 1090-3798

VL - 43

SP - A1

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

ER -

Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this